altretamine has been researched along with Adenocarcinoma, Basal Cell in 34 studies
Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan." | 9.04 | Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978) |
| "A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer." | 7.66 | Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981) |
| "A prospective randomized study was conducted in women with suboptimal (greater than or equal to 3 cm residual) Stage III, Stage IV, and recurrent ovarian adenocarcinoma to determine if combination chemotherapy is more effective than melphalan alone in achieving remission and improving survival." | 5.05 | A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. ( Blessing, JA; Buchsbaum, HJ; Homesley, HD; Leone, L; Miller, A; Morrow, CP; Omura, GA, 1983) |
| "Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan." | 5.04 | Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978) |
| "A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer." | 3.66 | Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981) |
| "Clinical investigation of epithelial ovarian cancer must involve the precise definition of the lesion, careful application of new techniques, the objective evaluation of such techniques, the comparison of results in a randomized fashion with prior forms of therapy, careful pathological evaluation of the tumour, and the evaluation of toxicity to the patient." | 2.65 | Mayo Clinic experience with epithelial ovarian cancer. ( Decker, DG, 1983) |
| "The lack of decisive progress in ovarian cancer chemotherapy in recent years led the ARTAC "Ovary" group to initiate a study based on the hypothesis of collateral sensitivities." | 1.28 | [Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group]. ( Coiffier, B; Facchini, T; Filippi, MH; Goudier, MJ; Goupil, A; Mignot, L; Pinel, MC; Pinon, G; Roullet, B; Tresca, P, 1991) |
| "Thirty-eight women with advanced ovarian cancer resistant to alkylating-agent chemotherapy were treated with a combination of hexamethylmelamine and cisplatin." | 1.26 | Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy. ( Arseneau, JC; Davis, TE; Einhorn, N; Kaplan, BH; Pagano, M; Tunca, JC; Vogl, SE, 1982) |
| "Twenty-one patients with advanced ovarian cancer proven resistant to standard alkylating chemotherapy were evaluated in a prospective study of Hexamethylmelamine." | 1.26 | Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. ( Bender, RA; Chabner, BA; DeVita, VT; Fisher, RI; Johnson, BL; Young, RC, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 29 (85.29) | 18.7374 |
| 1990's | 3 (8.82) | 18.2507 |
| 2000's | 2 (5.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arya, K | 1 |
| Dandia, A | 1 |
| Vogl, SE | 2 |
| Pagano, M | 1 |
| Davis, TE | 1 |
| Einhorn, N | 1 |
| Tunca, JC | 1 |
| Kaplan, BH | 2 |
| Arseneau, JC | 1 |
| Hernandez, E | 1 |
| Rosenshein, NB | 1 |
| Villar, J | 1 |
| Dillon, MB | 1 |
| Ettinger, DS | 1 |
| Order, SE | 1 |
| Oldham, DS | 1 |
| Wampler, GL | 1 |
| Brower, MS | 1 |
| Coleman, M | 3 |
| Pasmantier, MW | 3 |
| Silver, RT | 3 |
| Mamaril, AP | 1 |
| Quiguyan, CC | 1 |
| Davis, BW | 1 |
| Goldhirsch, A | 1 |
| Locher, GW | 1 |
| Dreher, E | 1 |
| Greiner, R | 1 |
| Burki, K | 1 |
| Brunner, KW | 1 |
| Omura, GA | 1 |
| Morrow, CP | 1 |
| Blessing, JA | 1 |
| Miller, A | 1 |
| Buchsbaum, HJ | 1 |
| Homesley, HD | 1 |
| Leone, L | 1 |
| Hainsworth, JD | 2 |
| Malcolm, A | 1 |
| Johnson, DH | 1 |
| Burnett, LS | 2 |
| Jones, HW | 2 |
| Greco, FA | 2 |
| Decker, DG | 1 |
| Piver, MS | 1 |
| Barlow, JJ | 2 |
| Lele, SB | 2 |
| Malfetano, JH | 1 |
| McPhee, ME | 1 |
| Stehman, FB | 1 |
| Ehrlich, CE | 1 |
| Callangan, MF | 1 |
| Bruckner, HW | 1 |
| Cohen, CJ | 1 |
| Deppe, G | 1 |
| Kabakow, B | 1 |
| Wallach, R | 1 |
| Ratner, L | 1 |
| Holland, JF | 1 |
| Chang, YC | 1 |
| Falkson, G | 1 |
| Tormey, DC | 1 |
| Crowley, J | 1 |
| Dorval, T | 1 |
| Beuzeboc, P | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Livartowski, A | 1 |
| Palangie, T | 1 |
| Pouillart, P | 1 |
| Lotz, JP | 1 |
| Lhommé, C | 1 |
| Pautier, P | 1 |
| Couteau, C | 1 |
| Gligorov, J | 1 |
| Alexandre, J | 1 |
| Selle, F | 1 |
| Izrael, V | 1 |
| Maraninchi, D | 1 |
| Viens, P | 1 |
| Mintz, U | 1 |
| Bitran, JD | 1 |
| Cooksey, JA | 1 |
| Desser, RK | 1 |
| DeMeester, TR | 1 |
| Golomb, HM | 1 |
| Young, RC | 2 |
| Chabner, BA | 2 |
| Hubbard, SP | 1 |
| Fisher, RI | 2 |
| Bender, RA | 2 |
| Anderson, T | 1 |
| Simon, RM | 1 |
| Canellos, GP | 1 |
| DeVita, VT | 2 |
| Johnson, BL | 1 |
| Krauss, S | 1 |
| Tornyos, K | 1 |
| DeSimone, P | 1 |
| Lowenbraun, S | 1 |
| McKeown, J | 1 |
| Solomon, A | 1 |
| Sonoda, T | 1 |
| Greenwald, E | 1 |
| Moukhtar, M | 1 |
| Wollner, D | 1 |
| Byrd, R | 1 |
| Wilson, WL | 1 |
| Ryzin, JV | 1 |
| Weiss, AJ | 1 |
| Frelick, RW | 1 |
| Moss, SE | 1 |
| Pinon, G | 1 |
| Pinel, MC | 1 |
| Goudier, MJ | 1 |
| Coiffier, B | 1 |
| Filippi, MH | 1 |
| Goupil, A | 1 |
| Roullet, B | 1 |
| Facchini, T | 1 |
| Mignot, L | 1 |
| Tresca, P | 1 |
| Boogerd, W | 1 |
| ten Bokkel Huinink, WW | 1 |
| Dalesio, O | 1 |
| Hoppenbrouwers, WJ | 1 |
| van der Sande, JJ | 1 |
| Strnad, CM | 1 |
| Grosh, WW | 1 |
| Baxter, J | 1 |
| Rizel, S | 1 |
| Biran, S | 1 |
| Anteby, SO | 1 |
| Brufman, G | 1 |
| Sulkes, A | 1 |
| Milwidsky, A | 1 |
| Weshler, Z | 1 |
| Fuks, Z | 1 |
| Chauvergne, J | 1 |
| Avril, A | 1 |
| Pigneux, J | 1 |
| Mage, P | 1 |
| Granger, C | 1 |
| Rosen, GF | 1 |
| Lurain, JR | 1 |
| Newton, M | 1 |
| Ross, WM | 1 |
| Carmichael, JA | 1 |
| Shelley, WE | 1 |
| Ballard, WP | 1 |
| Fuller, AF | 1 |
| Krane, IM | 1 |
| Budzik, GP | 1 |
| Donahoe, PK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma[NCT00226915] | Phase 3 | 637 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for altretamine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
[High-dose chemotherapy in ovarian adenocarcinoma].
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophospha | 2000 |
8 trials available for altretamine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; D | 1983 |
Mayo Clinic experience with epithelial ovarian cancer.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1983 |
Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Tri | 1984 |
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1993 |
Hexamethylmelamine, bleomycin, and CCNU chemotherapy for patients with squamous cell carcinoma, large cell carcinoma, and adenocarcinoma of the lung unresponsive to cyclophosphamide, adriamycin, methotrexate, and procarbazine.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Bleomycin; Carcinoma, Small Cell; Carcinoma, Squamous Cell | 1978 |
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Administrati | 1978 |
cis-Dichlorodiammineplatinum(II) and hexamethylmelamine in the treatment of non-oat cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical T | 1979 |
A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
Topics: Adenocarcinoma; Altretamine; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Top | 1975 |
25 other studies available for altretamine and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Synthesis and cytotoxic activity of trisubstituted-1,3,5-triazines.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; I | 2007 |
Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Cisplatin; Cystadenocarcinoma; D | 1982 |
Alternating multiagent chemotherapy for advanced ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Agents; Cisplatin; Cyclophosph | 1983 |
Hexamethylmelamine in adenocarcinoma of the pancreas and liver.
Topics: Adenocarcinoma; Altretamine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middl | 1983 |
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Combined Chemotherapy Protocol | 1984 |
Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluat | 1984 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1983 |
Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1984 |
Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug T | 1981 |
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; | 1981 |
Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Altretamine; Bone Marrow; Drug Resistance; Female; H | 1978 |
Ovarian cancer. Effective treatment after alkylating-agent failure.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Cisplatin; Cystadenoma; Doxorubicin; Drug Therapy, Combina | 1979 |
Ovarian endometrioid carcinoma in an eleven-year-old child.
Topics: Adenocarcinoma; Altretamine; Child; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat | 1979 |
[Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group].
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1991 |
Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervous Syste | 1990 |
Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 1989 |
Combined modality treatment for stage III ovarian carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Combined Chemothe | 1985 |
[Current role of chemotherapy in the treatment of adenocarcinomas of the endometrium].
Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophospha | 1986 |
Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1987 |
Advanced carcinoma of the ovary with central nervous system relapse.
Topics: Adenocarcinoma; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1988 |
HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
Topics: Adenocarcinoma; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclop | 1985 |
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Topics: Adenocarcinoma; Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1985 |
Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Deoxyguanosine; Dianhydrogalactitol; Drug Evalua | 1985 |
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin | 1985 |